This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2006 Aug;152(2):197-9.

doi: 10.1016/j.ahj.2006.05.022.

The COX-2 inhibitors--an update

PMID: 16875896
DOI: 10.1016/j.ahj.2006.05.022

Editorial

The COX-2 inhibitors--an update

Curt D Furberg. Am Heart J. 2006 Aug.

. 2006 Aug;152(2):197-9.

doi: 10.1016/j.ahj.2006.05.022.

Author

PMID: 16875896
DOI: 10.1016/j.ahj.2006.05.022

No abstract available

PubMed Disclaimer

Comment on

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Cannon CP, Curtis SP, Bolognese JA, Laine L; MEDAL Steering Committee. Cannon CP, et al. Am Heart J. 2006 Aug;152(2):237-45. doi: 10.1016/j.ahj.2006.05.024. Am Heart J. 2006. PMID: 16875903

Similar articles

Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J. Couzin J. Science. 2005 Feb 25;307(5713):1183-5. doi: 10.1126/science.307.5713.1183a. Science. 2005. PMID: 15731414 No abstract available.
Raising the safety bar--the FDA's coxib meeting.
Okie S. Okie S. N Engl J Med. 2005 Mar 31;352(13):1283-5. doi: 10.1056/NEJMp058055. N Engl J Med. 2005. PMID: 15800221 No abstract available.
COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM. Drazen JM. N Engl J Med. 2005 Mar 17;352(11):1131-2. doi: 10.1056/NEJMe058038. Epub 2005 Feb 15. N Engl J Med. 2005. PMID: 15713947 No abstract available.
COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV, Barnett EM, Randels CL. Bobadilla RV, et al. Adv Nurse Pract. 2005 Nov;13(11):48-50. Adv Nurse Pract. 2005. PMID: 16295003 Review. No abstract available.
COX-2 inhibitors and heart.
Manoria P, Manoria PC. Manoria P, et al. Indian Heart J. 2005 Nov-Dec;57(6):772-7. Indian Heart J. 2005. PMID: 16521658 Review. No abstract available.

See all similar articles

Cited by

Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study.
Wheeler BW, Metcalfe C, Gunnell D, Stephens P, Martin RM. Wheeler BW, et al. Br J Clin Pharmacol. 2009 Nov;68(5):752-64. doi: 10.1111/j.1365-2125.2009.03500.x. Br J Clin Pharmacol. 2009. PMID: 19917000 Free PMC article.
A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery.
Sandoval HP, Fernández de Castro LE, Vroman DT, Solomon KD. Sandoval HP, et al. Clin Ophthalmol. 2007 Dec;1(4):367-71. Clin Ophthalmol. 2007. PMID: 19668513 Free PMC article.
The ubiquitin- and proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs.
Neuss H, Huang X, Hetfeld BK, Deva R, Henklein P, Nigam S, Mall JW, Schwenk W, Dubiel W. Neuss H, et al. J Mol Med (Berl). 2007 Sep;85(9):961-70. doi: 10.1007/s00109-007-0197-y. Epub 2007 Apr 11. J Mol Med (Berl). 2007. PMID: 17429597

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Research Materials
- NCI CPTC Antibody Characterization Program